Nasdaq Biotechnology Ishares ETF (IBB)
$137.26
0.65 (0.47%)
IBB Stock Quote Delayed 30 Minutes
Buy Biotech’s Burst Bubble… Just Not Quite Yet
Delay purchases unless several strong days of selling drive it to its 200-day moving average.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.28M
Day's Range
$136.42 - $138.33
52-Week Range
$111.83 - $141.16
Dividend & Yield
$0.61 (0.45%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
You’re Way Too Late for These 2 Sector Parties
Amid a flat market, it's awfully tempting to chase hot-running biotech stocks and solar stocks higher. But keep your finger off the trigger.
I’m Bullish, but Not Ready to Buy
The bulls are making headway against a barrage of bad news but facing very tenacious resistance.
Watch for a New Buy Signal in This Sector Today
Momentum has been accelerating in this market-leading group.
Among Biotechs, Amgen Stock Offers Dividend Income
Biotech giant AMGN has a nice benefit Amgen stock in that it pays a dividend. With a low payout ratio, investors should look for increases in the future.
Stick With the Trend in This Overbought Sector
Biotechs been plodding along, forming a very steady bull channel.
GILD: Get on While Biotech Remains Hot
The bulls seemingly are unwilling to cast off biotech. And among the sector's biggest stocks, Gilead Sciences (GILD) has the most appealing setup.
Don’t Bet Against Biotech in 2013 … or Ever
Betting against biotech is usually a dangerous game for retail investors -- add leverage and you're entering Crazytown.
This Top Sector Should Continue to Outperform
iShares Nasdaq Biotechnology (IBB) is trading within a powerful bull channel and just flashed a new buy signal.
How to Profit From Every Biotech Buyout
Amgen's acquisition of Onyx underscores the fact that one simple biotech investment may also be the best one.
Changing U.S. Demographics Mean a Decades-Long Healthcare Boom
The aging of America's boomers is a compelling macro trend at work. And there's no better way to play that trend than via these ETFs.
The Best & Worst ETFs in 2013’s First Half
Some of the market's biggest headlines -- as well as a couple hidden stories -- are reflected in this list of the best and worst ETFs so far in 2013.
5 ETFs Set to Soar in the Second Half of 2013
The best way to invest amid a cloudy outlook is longer-term and lower-risk. One of the easiest ways to take on that kind of strategy is to buy diversified ETFs.
